slc38a7 Antibody

What is SLC38A7/SNAT7 and what cellular functions does it perform?

SLC38A7, also known as SNAT7, is a member of the SLC38 family that encodes sodium-coupled neutral amino acid transporters. It functions as a system N transporter with a strong substrate preference for L-glutamine. Beyond glutamine, SLC38A7 also transports other amino acids with polar side chains, as well as L-histidine and L-alanine .

Recent research has identified SLC38A7 as the primary lysosomal glutamine exporter. It plays a critical role in the export of glutamine and asparagine from the lysosomal lumen to the cytosol following protein degradation. This function is essential for maintaining amino acid homeostasis and supporting cellular metabolism, particularly in environments with limited free glutamine availability .

SLC38A7 is expressed in all neurons but not in astrocytes in the mouse brain. Notably, it is the first system N transporter identified to be expressed in GABAergic neurons. Its axonal localization near the synaptic cleft suggests an important function in the reuptake and recycling of glutamate in neuronal tissues .

What applications can SLC38A7 antibodies be validated for?

Current commercially available SLC38A7 antibodies have been validated for multiple research applications, as shown in the following table:

The antibody 83346-6-RR has been specifically validated for WB, FC (Intracellular), and ELISA applications with proven reactivity against human samples . Additionally, the antibody 83346-3-PBS has been validated as part of a matched antibody pair (MP00351-3) for cytometric bead array applications .

How should SLC38A7 antibodies be properly stored and handled to maintain reactivity?

The storage and handling requirements depend on the specific formulation of the SLC38A7 antibody:

For antibody 83346-6-RR:

• Store at -20°C

• Stable for one year after shipment

• Aliquoting is unnecessary for -20°C storage

• 20 μl sizes contain 0.1% BSA

• Provided in PBS with 0.02% sodium azide and 50% glycerol pH 7.3

For antibody 83346-3-PBS (conjugation ready format):

• Store at -80°C

• Provided in PBS only (BSA and azide free) at a concentration of 1 mg/mL

• This format is specifically designed for conjugation and makes the antibody ideal for ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications

When working with these antibodies, minimize freeze-thaw cycles and handle samples on ice when possible to preserve antibody integrity and reactivity.

Why is there a discrepancy between calculated and observed molecular weights for SLC38A7?

The calculated molecular weight for SLC38A7 is 50 kDa, but the observed molecular weight on immunoblots is approximately 37-40 kDa . This discrepancy is commonly observed with membrane proteins and can be attributed to several factors:

• Post-translational modifications such as proteolytic processing

• Incomplete denaturation during SDS-PAGE sample preparation

• Anomalous migration behavior of hydrophobic membrane proteins

• Tissue or cell type-specific processing differences

In HeLa cell homogenates, the SLC38A7 antibody HPA041777 detects a band at approximately 40 kDa. The identity of this band has been confirmed through CRISPR/Cas9 gene editing experiments, where homozygous disruption of the SLC38A7 gene abolished the 40 kDa band, confirming its specificity .

What cell lines and tissues have been validated for SLC38A7 antibody testing?

Based on the available research data, SLC38A7 antibodies have been successfully tested in the following biological samples:

For Western blot applications, positive signal detection has been confirmed in Caco-2 cells and human liver tissue . In neuronal studies, SLC38A7 expression has been demonstrated in all neurons but not in astrocytes in the mouse brain, including GABAergic neurons .

How can I validate the specificity of SLC38A7 antibodies for my experimental system?

Validating antibody specificity is crucial for obtaining reliable research results. For SLC38A7 antibodies, multiple validation strategies can be employed:

• Gene silencing or knockout approaches:

  • CRISPR/Cas9 gene editing: The specificity of SLC38A7 antibodies has been validated using CRISPR/Cas9 nickase method to create SLC38A7-knockout HeLa cells. Homozygous disruption of SLC38A7 abolished the 40-kDa band on immunoblots, confirming antibody specificity .

• Rescue experiments:

  • After knockdown or knockout of endogenous SLC38A7, overexpress mouse SNAT7 to rescue the phenotype and confirm antibody specificity through restored signal detection .

• Comparison across multiple antibodies:

  • Test multiple antibodies targeting different epitopes of SLC38A7, such as 83346-6-RR and HPA041777, to confirm consistent patterns of reactivity.

• Subcellular fractionation:

  • Validate the lysosomal localization of SLC38A7 through subcellular fractionation experiments, as demonstrated in previous studies showing enrichment in lysosome-containing fractions .

What are the optimal protocols for using SLC38A7 antibodies in Western blot and flow cytometry?

Western Blot Protocol Optimization:

• Sample preparation:

  • Prepare cell or tissue lysates in a buffer containing protease inhibitors

  • Include positive controls (Caco-2 cells, human liver tissue) and negative controls (SLC38A7 knockout cells if available)

• Gel electrophoresis and transfer:

  • Use 10-12% polyacrylamide gels for optimal resolution of the 37-40 kDa SLC38A7 protein

  • Transfer to PVDF or nitrocellulose membranes using standard protocols

• Blocking and antibody incubation:

  • Block membrane in 5% non-fat milk or BSA in TBST

  • Incubate with primary antibody at recommended dilution (1:2000-1:10000 for 83346-6-RR)

  • For optimal results, incubate overnight at 4°C with gentle rocking

  • Wash thoroughly and incubate with appropriate HRP-conjugated secondary antibody

• Detection and analysis:

  • Develop using enhanced chemiluminescence

  • Expected band size: 37-40 kDa (observed), though calculated MW is 50 kDa

Flow Cytometry Protocol Optimization (Intracellular Staining):

• Cell preparation:

  • Harvest cells (Caco-2 or U-251 cells work well) in single-cell suspension

  • Fix and permeabilize cells using a commercial kit suitable for intracellular proteins

• Staining procedure:

  • Block with 2-5% normal serum from the same species as the secondary antibody

  • Incubate with SLC38A7 antibody at recommended concentration (0.25 μg per 10^6 cells in 100 μl suspension for 83346-6-RR)

  • Wash and incubate with fluorophore-conjugated secondary antibody

  • Include appropriate isotype controls

• Analysis:

  • Analyze using standard flow cytometry protocols

  • Use SLC38A7 knockout cells as negative controls where possible

What experimental considerations are important when studying SLC38A7 in lysosomal function research?

When investigating SLC38A7 in the context of lysosomal function, several key experimental considerations should be addressed:

• Lysosomal pH dependency:

  • SLC38A7 transport activity is strongly dependent on the lysosomal pH gradient. Experiments using the proton ionophore FCCP or the H+/K+ exchanger nigericin that disrupt this gradient have been shown to abolish SLC38A7-mediated glutamine transport .

  • Include controls with bafilomycin A1 (V-type H+-ATPase inhibitor) to assess the dependency on lysosomal acidification.

• Substrate selectivity assessments:

  • SLC38A7 is highly selective for glutamine and asparagine, unlike other characterized members of the SLC38 family. This selectivity applies to both sides of the lysosomal membrane .

  • When designing experiments to study SLC38A7 transport function, include controls with various amino acids to confirm this selectivity.

• Lysosomal isolation techniques:

  • For subcellular fractionation studies, optimize protocols for isolation of lysosomes to study native SLC38A7.

  • Consider using density gradient centrifugation methods and validate the purity of lysosomal fractions with established markers.

• TFEB-based assays:

  • Consider employing the TFEB-based assay that detects lysosomal amino acid export. This approach has been used successfully to identify SLC38A7 as a lysosomal transporter highly selective for glutamine and asparagine .

• Cancer cell metabolism studies:

  • When studying SLC38A7 in cancer cells, consider experimental conditions with low free-glutamine environments, where macropinocytosis and lysosomal degradation of extracellular proteins are used as alternative sources of amino acids .

How can CRISPR/Cas9 gene editing be used to validate SLC38A7 antibody specificity and study protein function?

CRISPR/Cas9 gene editing provides a powerful approach for validating antibody specificity and studying SLC38A7 function. The following methodology has been validated in previous research:

• CRISPR/Cas9 nickase approach for SLC38A7 gene disruption:

  • Use the D10A mutant of Cas9 (Cas9n) to reduce off-target effects

  • Design sgRNAs targeting the first coding exon of SLC38A7 (approximately 130 bp downstream of the initiation codon)

  • Target opposite strands of the DNA to create specific double-strand breaks

• Validated sgRNA design and transfection:

  • Transfect cells with two plasmids expressing sgRNAs complementary to opposite strands, along with scaffold RNA and Cas9n

  • Select transfected cells using puromycin (1 μg/mL) for 3-6 days in complete medium

• Clone isolation and genotyping:

  • Isolate clones by serial dilution cloning

  • Genotype by PCR amplification using primers targeting the region (validated primers: 5′-TGTCTCCCCATACTCTGGCA-3′ and 5′-CTCCCTTTTGAGGCAAAGCG-3′)

  • Confirm gene disruption by sequencing

• Validation of gene editing:

  • For heterozygously edited clones, subclone PCR products into a plasmid (e.g., pCR-Blunt-II-TOPO)

  • Sequence multiple bacterial clones per cell clone to confirm all alleles

  • Generate proper negative controls using plasmids expressing solely scaffold RNA and Cas9n

• Antibody validation:

  • Compare antibody reactivity between wild-type and SLC38A7-knockout cells using Western blot

  • Confirmed SLC38A7 knockout should result in loss of the specific 40 kDa band on immunoblots

This approach not only validates antibody specificity but also provides valuable cellular models for studying SLC38A7 function through comparison of wild-type and knockout phenotypes.

What approaches can be used to study SLC38A7 in glutamine metabolism of cancer cells?

SLC38A7 plays a critical role in cancer cell glutamine metabolism, particularly in low glutamine environments. The following experimental approaches are recommended for investigating this role:

• Cell growth assays in glutamine-restricted conditions:

  • Compare growth of wild-type and SLC38A7-deficient cancer cells (CRISPR knockout or siRNA knockdown) in media with varying glutamine concentrations

  • Include conditions with extracellular proteins as alternative amino acid sources to assess the role of SLC38A7 in utilizing protein-derived glutamine

• Macropinocytosis and protein degradation assays:

  • Monitor macropinocytosis rates using fluorescent dextran uptake

  • Assess the ability of cells to utilize extracellular proteins for growth in glutamine-limited conditions

  • Compare protein degradation rates between wild-type and SLC38A7-deficient cells

• Glutamine flux measurements:

  • Use radiolabeled glutamine ([3H]glutamine) to measure transport across lysosomal membranes

  • Implement countertransport assays to assess selective transport of glutamine and asparagine

  • Include controls with ionophores (FCCP, valinomycin, nigericin) and V-ATPase inhibitors (bafilomycin A1) to assess the role of pH gradient in transport activity

• Metabolomic analysis:

  • Compare metabolite profiles between wild-type and SLC38A7-deficient cancer cells

  • Focus on glutamine-derived metabolites to track the metabolic fate of lysosomal glutamine

  • Integrate results with transcriptomic data to identify compensatory mechanisms

• Combined gene silencing approaches:

  • Use the validated DsiRNAs (S7-1, S7-2, S7-3) for SLC38A7 silencing in cancer cell lines

  • Implement the established protocol:

    • Day 1: Seed cells (225,000 MIA PaCa-2 or 200,000 A2780 cells per well)

    • Day 2: Initiate silencing with 5 pmol DsiRNA and 2 μL Lullaby transfection reagent

    • Day 3: Replace medium

    • Day 4: Second transfection with 2.5 pmol DsiRNA and 0.4 μg plasmid DNA

    • Day 5: Assay cells

These approaches provide a comprehensive framework for investigating the role of SLC38A7 in cancer cell glutamine metabolism and may reveal potential therapeutic targets for glutamine-related anticancer therapies.

What strategies can help resolve weak or inconsistent SLC38A7 detection in Western blot?

When encountering weak or inconsistent SLC38A7 detection in Western blot experiments, consider the following troubleshooting approaches:

• Protein extraction optimization:

  • Use specialized lysis buffers designed for membrane proteins

  • Include adequate protease inhibitors to prevent degradation

  • Consider different detergents (RIPA, NP-40, Triton X-100) to optimize SLC38A7 solubilization

• Sample handling:

  • Avoid repeated freeze-thaw cycles of protein samples

  • Maintain samples at 4°C during preparation and loading

  • Do not boil samples for extended periods, as this may cause aggregation of membrane proteins

• Antibody concentration adjustment:

  • Test a range of primary antibody dilutions (1:2000-1:10000 as recommended for 83346-6-RR)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Ensure antibodies are stored properly to maintain reactivity

• Blocking optimization:

  • Test different blocking agents (BSA vs. non-fat milk)

  • Adjust blocking time and temperature

  • Include 0.1-0.3% Tween-20 in washing buffers to reduce background

• Detection enhancement:

  • Use more sensitive detection substrates for weak signals

  • Increase exposure time during imaging

  • Consider signal amplification methods like biotin-streptavidin systems

• Verification with positive controls:

  • Include known positive samples (Caco-2 cells, human liver tissue)

  • Run multiple antibodies targeting different epitopes of SLC38A7 in parallel

Remember that SLC38A7 is observed at 37-40 kDa rather than the calculated 50 kDa , so ensure you are examining the correct molecular weight range.

What is the optimal approach for determining antibody concentration for specific applications?

Determining the optimal antibody concentration requires systematic titration for each specific application. Follow these methodological approaches for common techniques:

• Western Blot titration:

  • Start with the recommended range (1:2000-1:10000 for 83346-6-RR)

  • Prepare a dilution series (e.g., 1:1000, 1:2000, 1:5000, 1:10000)

  • Use identical samples across all dilutions

  • Evaluate signal-to-noise ratio, specificity, and background at each concentration

  • Select the dilution that provides the strongest specific signal with minimal background

• Flow Cytometry optimization:

  • Begin with the recommended concentration (0.25 μg per 10^6 cells in 100 μl)

  • Test a range above and below this concentration (e.g., 0.1, 0.25, 0.5, 1.0 μg)

  • Include appropriate isotype controls at matching concentrations

  • Analyze signal intensity, separation from negative control, and non-specific binding

  • Calculate the staining index (mean positive - mean negative / 2 × SD of negative) at each concentration

• ELISA and multiplex assay optimization:

  • For 83346-3-PBS in matched antibody pairs, perform a checkerboard titration

  • Systematically vary both capture and detection antibody concentrations

  • Evaluate sensitivity, dynamic range, and background at each combination

  • Confirm specificity with appropriate controls

• General principles for all applications:

  • The manufacturer's recommended range should be considered a starting point

  • Each application, cell type, and experimental condition may require unique optimization

  • Document all optimization steps for reproducibility

  • The statement "It is recommended that this reagent should be titrated in each testing system to obtain optimal results" emphasizes the importance of application-specific optimization

Antibody performance can vary between lots and over time, so periodic revalidation of optimal concentrations is advised, particularly when working with new batches of antibody.

What controls are essential when using SLC38A7 antibodies in research applications?

Implementing appropriate controls is critical for ensuring the validity and interpretability of experiments using SLC38A7 antibodies. The following controls should be considered for different applications:

• Positive controls:

  • Cell lines with confirmed SLC38A7 expression: Caco-2 cells and U-251 cells have been validated for antibody 83346-6-RR

  • Tissue samples with known expression: Human liver tissue has shown positive reactivity

  • Recombinant SLC38A7 protein as a reference standard where applicable

• Negative controls:

  • SLC38A7 knockout cells generated using CRISPR/Cas9 (as described in the literature)

  • Cells treated with validated SLC38A7-specific siRNAs (S7-1, S7-2, S7-3)

  • Primary antibody omission controls to assess non-specific binding of secondary antibodies

  • Isotype controls for flow cytometry applications

• Specificity controls:

  • Blocking peptide competition assays to confirm epitope specificity

  • Comparison of staining patterns using multiple antibodies targeting different SLC38A7 epitopes

  • Rescue experiments: reintroduction of SLC38A7 into knockout cells should restore antibody reactivity

• Technical controls:

  • Loading controls for Western blot (e.g., β-actin, GAPDH)

  • Subcellular fractionation markers to confirm proper isolation of lysosomal fractions when studying SLC38A7 localization

  • For functional studies of SLC38A7 transport activity:

    • ATP depletion controls

    • Bafilomycin A1 treatment to inhibit V-type H+-ATPase

    • Ionophores (FCCP, nigericin) to disrupt the lysosomal pH gradient

• Validation across multiple experimental approaches:

  • Confirm protein expression results with mRNA expression analysis

  • Validate antibody-based localization with fluorescent protein tagging

  • Corroborate immunostaining results with subcellular fractionation

Implementing these comprehensive controls will ensure robust and reproducible results when using SLC38A7 antibodies in research applications.